{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 73,
  "pageCount": 76,
  "prevPage": 72,
  "nextPage": 74,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The table uses a heatmap-style color coding (red/green) to indicate risk levels for UGT1A1 inhibition parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/73",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-73",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.42,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "list",
      "text": "‘565 has a low risk of potential DDI/ hyperbilirubinaemia at predicted human efficacious doses. Potential for safer dose escalation for ‘565 to reach the level of target engagement necessary to achieve clinical efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3abc4d1f-ce63-4251-b1ac-ba6d0cd97559",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.42,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "We predict that selectivity over UGT1A1 could be an issue for some clinical stage MALT1 inhibitors. Inhibition of UGT1A1 mediates bilirubin glucuronidation, potentially leading to hyperbilirubinaemia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b347f6d-503d-43ba-a1c0-355ad605af69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023. 1) Hertzberg et al. Hematol Oncol, 2023; Cmax,u: Predicted maximum free plasma; Imax,u,inlet: free liver inlet concentration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9666b688-e022-46cd-a13c-9756d4d4513f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.6
      },
      "kind": "table",
      "text": "Comparison table of Pharma Phase 1b vs '565 across UGT1A1 parameters (IC50, Rfree, Rin,free, Fi) and risk prediction.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41ec41fd-3777-455e-b0b6-5d44ba77a8cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Potential safety benefit compared with clinical MALT1i in development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78adff99-cedf-4740-8b4f-b30dd8ed395f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 has a low predicted risk of hyperbilirubinaemia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe25dcb6-ab05-43e6-98e0-700450a1cdd2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "78c92762-ca4c-4c8f-adb1-a4589b03baca",
      "evidence": "table/data: Comparison table of Pharma Phase 1b vs '565 across UGT1A1 parameters (IC50, Rfree, Rin,free, Fi) and risk prediction.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "dc598587-63c2-46d2-8048-5ffd4c2a2805",
      "evidence": "Direct comparison of two compounds across multiple quantitative safety metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}